secwatch.observer — SEC 8-K summary
======================================

Issuer:     ABEONA THERAPEUTICS INC. (ABEO)
CIK:        0000318306
Form:       8-K
Filed at:   2026-06-04T11:30:38+00:00
Accession:  0001493152-26-027197
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Abeona holds constructive Pre-IND meeting with FDA for ABO-701; IND target 2027
-------------------------------------------------------------------------------

- Pre-IND meeting with FDA held June 3, 2026 for ABO-701, a T-cell therapy targeting PSMA for prostate cancer.
- Company characterizes meeting as constructive; official FDA minutes not yet received.
- IND submission for ABO-701 remains targeted for 2027, consistent with prior guidance.
- No assurance that FDA will accept IND or that additional studies won't be required.
- Development plans subject to revision based on FDA feedback, preclinical results, and manufacturing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/318306/000149315226027197/0001493152-26-027197-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/318306/000149315226027197/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-027197

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer